Paediatric therapeutic development workshop on medulloblastoma.
Global expert consensus maps priority targets and combinations for childhood brain tumor trials, accelerating high-risk treatment development.
This consensus output from the second Paediatric Therapeutic Development Workshop on medulloblastoma, involving leading investigators from St. Jude, DKFZ, Cambridge, and 35 other centres, maps the highest-priority therapeutic targets and trial-ready combinations for this rare childhood brain tumour where 30–40% of patients die and survivors face severe long-term side effects. It provides a blueprint for international early-phase trial design for high-risk subgroups.
What the study was
- Study design
- expert_consensus_workshop
- Category
- rare_diseases
- Maturity
- Validated
- Journal
- Br J Cancer
Why it surfaced
British Journal of Cancer; high unmet need in paediatric brain tumours (<10% survival in high-risk groups); identifies B7-H3 CAR-T and targeted degrader approaches with near-term trial readiness; clinical_applicability capped at 0 as workshop consensus without clinical trial data; represents the current standard for medulloblastoma drug development roadmap.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.